DCLK1 induces a pro-tumorigenic phenotype to drive gastric cancer progression.

Autor: Afshar-Sterle S; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Carli ALE; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., O'Keefe R; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Tse J; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Fischer S; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Azimpour AI; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Baloyan D; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Elias L; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Thilakasiri P; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Patel O; ACRF Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Ferguson FM; Department of Chemistry and Biochemistry and the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA., Eissmann MF; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Chand AL; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Gray NS; Department of Chemical and Systems Biology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Busuttil R; Central Clinical School, Monash University, Melbourne, VIC, Australia.; Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia., Boussioutas A; Central Clinical School, Monash University, Melbourne, VIC, Australia.; Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia., Lucet IS; ACRF Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Ernst M; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia., Buchert M; Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia.

Publikováno v: Science signaling [Sci Signal] 2024 Sep 17; Vol. 17 (854), pp. eabq4888. Date of Electronic Publication: 2024 Sep 17.

A tuft cell - ILC2 signaling circuit provides therapeutic targets to inhibit gastric metaplasia and tumor development.

Autor: O'Keefe RN; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Carli ALE; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Baloyan D; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Chisanga D; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Shi W; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Afshar-Sterle S; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Eissmann MF; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Poh AR; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Pal B; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Seillet C; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Department of Medical Biology, University of Melbourne, Melbourne, Australia., Locksley RM; Department of Medicine, University of California San Francisco, San Francisco, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, USA., Ernst M; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia., Buchert M; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia. Michael.buchert@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Bundoora, Australia. Michael.buchert@onjcri.org.au.

Publikováno v: Nature communications [Nat Commun] 2023 Oct 28; Vol. 14 (1), pp. 6872. Date of Electronic Publication: 2023 Oct 28.

Dual MAPK and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death

Autor: Iatropoulos G, Kael Schoffer, Fairlie Wd, Laura J. Jenkins, John M. Mariadason, Vukelic N, Jayesh Desai, Matthias Ernst, Michelle Palmieri, Tan T, Tse Jw, Lee Ef, Niall C. Tebbutt, Rebecca Nightingale, Oliver M. Sieber, Amardeep S. Dhillon, Afshar-Sterle S, Ng I, Peter Gibbs, Ian Y. Luk, Alam Z

The EGFR/RAS/MEK/ERK signalling pathway (ERK/MAPK) is hyper-activated in most colorectal cancers (CRCs). A current limitation of inhibitors of this pathway is that they primarily induce cytostatic effects in CRC cells. Nevertheless, these drugs do in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ddd1cc0414946f7bba038d2bc41e0f5
https://doi.org/10.1101/2021.02.15.431252

Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression.

Autor: Luk IY; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia.; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia., Jenkins LJ; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Schoffer KL; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Ng I; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Tse JWT; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia.; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia., Mouradov D; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia., Kaczmarczyk S; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Nightingale R; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Burrows AD; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia., Anderson RL; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Arango D; Group of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital Research Institute (VHIR), Barcelona, Spain.; Group of Molecular Oncology, Biomedical Research institute of Lleida (IRBLleida), Lleida, Spain., Dopeso H; Group of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital Research Institute (VHIR), Barcelona, Spain., Croft L; School of Life and Environmental Sciences, Deakin University, Geelong, VIC, Australia., Richardson MF; School of Life and Environmental Sciences, Deakin University, Geelong, VIC, Australia., Sieber OM; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.; Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.; Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia., Liao Y; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Mooi JK; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia., Vukelic N; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Reehorst CM; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Afshar-Sterle S; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Whitehall VLJ; QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.; Conjoint Internal Medicine Laboratory, Pathology Queensland, Brisbane, QLD, Australia.; The University of Queensland, St Lucia, QLD, Australia., Fennell L; QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Abud HE; Development and Stem Cells Program and the Department of Anatomy and Developmental Biology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia., Tebbutt NC; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia.; Department of Surgery, The University of Melbourne, Parkville, VIC, Australia., Phillips WA; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.; Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Williams DS; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia.; Department of Anatomical Pathology, Austin Health, Heidelberg, VIC, Australia.; Department of Clinical Pathology, University of Melbourne, Parkville, VIC, Australia., Shi W; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia.; School of Computing and Information Systems, University of Melbourne, Parkville, VIC, Australia., Mielke LA; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Ernst M; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Dhillon AS; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia.; The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, VIC, Australia., Clemons NJ; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Mariadason JM; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia. john.mariadason@onjcri.org.au.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia. john.mariadason@onjcri.org.au.; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia. john.mariadason@onjcri.org.au.

Publikováno v: Cell death and differentiation [Cell Death Differ] 2022 Nov; Vol. 29 (11), pp. 2288-2302. Date of Electronic Publication: 2022 May 23.

Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells.

Autor: Carli ALE; Cancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Afshar-Sterle S; Cancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Rai A; Baker Heart and Diabetes Institute, Molecular Proteomics, Melbourne, Victoria, Australia.; Central Clinical School, Monash University, Melbourne, Victoria, Australia., Fang H; Baker Heart and Diabetes Institute, Molecular Proteomics, Melbourne, Victoria, Australia., O'Keefe R; Cancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Tse J; Cancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Ferguson FM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Ernst M; Cancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Greening DW; Baker Heart and Diabetes Institute, Molecular Proteomics, Melbourne, Victoria, Australia.; Central Clinical School, Monash University, Melbourne, Victoria, Australia.; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.; Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Victoria, Australia., Buchert M; Cancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.

Publikováno v: Proteomics [Proteomics] 2021 Jul; Vol. 21 (13-14), pp. e2000098. Date of Electronic Publication: 2021 May 28.